Spontaneous bacterial peritonitis prophylaxis
First line
Norfloxacin 400 mg daily is the first-line agent for secondary SBP prophylaxis in cirrhotic patients with ascites after a prior SBP episode. 2021 and 2018 endorse this recommendation. Primary prophylaxis is justified with low ascitic protein (below 15 g/L) and concurrent renal or hepatic dysfunction. The 2009 Cochrane review showed a 50-60% reduction in SBP risk and all-cause mortality. In light of fluoroquinolone risks per 2018 and 2019, prophylaxis duration and patient status are reassessed every 3-6 months.